<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098121</url>
  </required_header>
  <id_info>
    <org_study_id>TYGH105034</org_study_id>
    <nct_id>NCT03098121</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Grazoprevir and Elbasvir in Peginterferon Alfa Plus Ribavirin Experienced Patients With Chronic Genotype 1 HCV and HIV Co-infection: a Non-randomised, Open-label Clinical Trial</brief_title>
  <official_title>Efficacy and Tolerability of Grazoprevir and Elbasvir in Peginterferon Alfa Plus Ribavirin Experienced Patients With Chronic Genotype 1 HCV and HIV Co-infection: a Non-randomised, Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taoyuan General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Taoyuan General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate whether grazoprevir and elbasvir is efficacious, safe, and
      well-tolerated in peginterferon alfa plus ribavirin experienced patients who inject drugs
      (PWID) and men who sex with men (MSM) with genotype 1 HCV and HIV co-infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective •To assess the efficacy of grazoprevir 100mg and elbasvir 50mg by
      determining the proportion of sustained virological response 12 weeks after the end of
      therapy (SVR12; HCV RNA concentration less than 10 IU/ mL at follow-up week 12) in
      peginterferon alfa plus ribavirin experienced patients with genotype 1 HCV and HIV
      co-infection, compared with treatment-naïve patients with 1 HCV and HIV co-infection.

      Secondary Objective

      •To assess the tolerability of grazoprevir 100mg and elbasvir 50mg in peginterferon alfa plus
      ribavirin experienced patients by measuring frequency of SAEs and AEs leading to
      discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>12 weeks after the end of therapy</time_frame>
    <description>The proportion of sustained virological response 12 weeks after the end of therapy after the treatment of grazoprevir and elbasvir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe adverse effects</measure>
    <time_frame>during the treatment of grazoprevir and elbasvir</time_frame>
    <description>The frequency of severe adverse effects leading to discontinuation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>To Assess the Efficacy of Grazoprevir 100mg and Elbasvir 50mg by Determining the Proportion of Sustained Virological Response 12 Weeks After the End of Therapy</condition>
  <arm_group>
    <arm_group_label>peginterferon experienced patients with genotype 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention is to add grazoprevir 100mg and elbasvir 50mg in peginterferon alfa plus ribavirin experienced patients with genotype 1 HCV and HIV co-infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>grazoprevir and elbasvir</intervention_name>
    <description>For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir 100mg and elbasvir 50mg in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir 100mg and elbasvir 50mg in a fixed-dose combination tablet once daily for 12 weeks.</description>
    <arm_group_label>peginterferon experienced patients with genotype 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and non-pregnant women, at least 20 years of age with chronic genotype 1 HCV and
             HIV co-infection.

          -  HCV RNA &gt; 10,000 IU/mL

          -  Stable antiretroviral therapy (ARV) with confirmed plasma HIV-1 RNA &lt; 200 copies/mL

          -  CD4 T-cell count &gt; 100 cells/L

          -  peginterferon alfa plus ribavirin failure: null response &lt;1 log10 IU/mL reduction in
             HCV RNA at week 4; detectable HCV RNA since week 12 to the end of treatment;
             detectable HCV RNA for 12 to 24 weeks after the end of treatment; or discontinuation
             of peginterferon alfa plus ribavirin due to grade 3 or grade 4 adverse effects at any
             moment.

        Exclusion Criteria:

          -  Decompensated liver disease (presence or history of ascites, oesophageal or gastric
             variceal bleeding, hepatic encephalopathy, or other signs of advanced liver diseases)

          -  Liver cirrhosis with Child-Pugh class B or C, or with a Child-Turcotte-Pugh score of
             more than 6 points and albumin below 3 g/dL or platelet count below 75,000/ μL

          -  History of malignant disease, or evidence of hepatocellular carcinoma

          -  ARV with protease inhibitor containing regimen HBsAg and HBV core antibody should be
             checked in all patients. HBsAg positive patients should be excluded from the study.
             HBV core antibody positive patients should be closely monitored for hepatitis flare or
             HBV reactivation during HCV treatment and post-treatment follow-up. Appropriate
             patient management should be instituted for HBV infection as clinically indicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chien-Yu Cheng</last_name>
    <phone>+88633699721</phone>
    <phone_ext>8311</phone_ext>
    <email>vajien@mail.tygh.gov.tw</email>
  </overall_contact>
  <reference>
    <citation>Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, Bonet L, Vidal F, Milinkovic A, Bassa A, Villalonga C, Pérez I, Tural C, Martínez-Rebollar M, Calvo M, Blanco JL, Martínez E, Sánchez-Tapias JM, Gatell JM, Mallolas J. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009 Jan;49(1):22-31. doi: 10.1002/hep.22598. Erratum in: Hepatology. 2009 Mar;49(3):1058.</citation>
    <PMID>19085908</PMID>
  </reference>
  <reference>
    <citation>Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29;351(5):451-9.</citation>
    <PMID>15282352</PMID>
  </reference>
  <reference>
    <citation>Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29;351(5):438-50.</citation>
    <PMID>15282351</PMID>
  </reference>
  <reference>
    <citation>Liu JY, Lin HH, Liu YC, Lee SS, Chen YL, Hung CC, Ko WC, Huang CK, Lai CH, Chen YS, Shih YL, Chung HC, Liang SH, Lin JN. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clin Infect Dis. 2008 Jun 1;46(11):1761-8. doi: 10.1086/587992.</citation>
    <PMID>18433337</PMID>
  </reference>
  <reference>
    <citation>Liu CH, Sheng WH, Sun HY, Hsieh SM, Lo YC, Liu CJ, Su TH, Yang HC, Liu WC, Chen PJ, Chen DS, Hung CC, Kao JH. Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. Sci Rep. 2015 Nov 30;5:17410. doi: 10.1038/srep17410.</citation>
    <PMID>26616669</PMID>
  </reference>
  <reference>
    <citation>Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.</citation>
    <PMID>26196665</PMID>
  </reference>
  <reference>
    <citation>Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC Jr, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P; ALLY-2 Investigators. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20;373(8):714-25. doi: 10.1056/NEJMoa1503153. Epub 2015 Jul 21.</citation>
    <PMID>26196502</PMID>
  </reference>
  <reference>
    <citation>Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9. Erratum in: Lancet HIV. 2015 Aug;2(8):e316. Lancet HIV. 2015 Oct;2(10):e416.</citation>
    <PMID>26423374</PMID>
  </reference>
  <results_reference>
    <citation>Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol. 2013 Sep 27;5(9):496-504. doi: 10.4254/wjh.v5.i9.496. Review.</citation>
    <PMID>24073301</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study will be conducted at 3 different hospitals, and we will share the data with other researchers every 3 months</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

